Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CD38抗体
Document Type and Number:
Japanese Patent JP7299873
Kind Code:
B2
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

Inventors:
Gouvier Anne
Salim Josephine
goyentea corso beatriz
Melhiels Pascal
moulder kevin
Eisler Nina
Philost Simone
Balua Hemanta
Prinz Bianca
Application Number:
JP2020508320A
Publication Date:
June 28, 2023
Filing Date:
August 16, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Black Belt Therapeutics Limited
International Classes:
C12N15/13; A61K39/395; A61K45/00; A61P35/00; A61P43/00; C07K16/28; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08
Domestic Patent References:
JP2010506582A
Other References:
DECKERT, J. et al.,SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies,Clinical cancer research,2014年,20,4574-4583
FENG, X. et al.,Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.,Clinical cancer research,2017年03月,23,4290-4300
Attorney, Agent or Firm:
Saegusa International Patent Office